2nd Quarter - Report

THE PETRIZZO GROUP, INC. for CEL-SCI CORPORATION

Period 2nd Quarter 2020 Filed Jul 9, 2020 Signed by T.J. Petrizzo, Chairman & CEO

Official filing
Firm
THE PETRIZZO GROUP, INC.
Client
CEL-SCI CORPORATION
Income
$50,000
Expenses
—

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Medical/Disease Research/Clinical Labs MED

Activity related to phase III clinical trial in head and neck cancer to boost the immune system before the ravages of surgery, radiation and chemotherapy. The Phase III trial is the largest ever in head and neck cancer with 928 patients enrolled. LEAPS COVID-19 Immunotherapyas a new immune-based treatment for COVID-19

LobbyistCovered position, as disclosed
TJ PETRIZZO —

Contacted: HOUSE OF REPRESENTATIVES; Natl Institutes of Health (NIH); Health & Human Services, Dept of (HHS); Food & Drug Administration (FDA); SENATE; Vice President of the U.S.

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.